Abbott Laboratories Stock Cash And Equivalents
| ABL Stock | EUR 108.06 0.44 0.41% |
Abbott Laboratories fundamentals help investors to digest information that contributes to Abbott Laboratories' financial success or failures. It also enables traders to predict the movement of Abbott Stock. The fundamental analysis module provides a way to measure Abbott Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abbott Laboratories stock.
Abbott |
Abbott Laboratories Company Cash And Equivalents Analysis
Abbott Laboratories' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Abbott Laboratories Cash And Equivalents | 8.37 B |
Most of Abbott Laboratories' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abbott Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Abbott Laboratories has 8.37 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Devices industry. The cash and equivalents for all Germany stocks is significantly lower than that of the firm.
Abbott Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abbott Laboratories' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abbott Laboratories could also be used in its relative valuation, which is a method of valuing Abbott Laboratories by comparing valuation metrics of similar companies.Abbott Laboratories is currently under evaluation in cash and equivalents category among its peers.
Abbott Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0738 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 190.22 B | |||
| Shares Outstanding | 1.74 B | |||
| Shares Owned By Insiders | 0.70 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 41.25 X | |||
| Price To Book | 5.40 X | |||
| Price To Sales | 3.91 X | |||
| Revenue | 43.65 B | |||
| Gross Profit | 24.58 B | |||
| EBITDA | 12.13 B | |||
| Net Income | 6.93 B | |||
| Cash And Equivalents | 8.37 B | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 14.52 B | |||
| Debt To Equity | 0.55 % | |||
| Current Ratio | 1.75 X | |||
| Book Value Per Share | 21.11 X | |||
| Cash Flow From Operations | 9.58 B | |||
| Earnings Per Share | 3.69 X | |||
| Price To Earnings To Growth | 18.63 X | |||
| Target Price | 132.05 | |||
| Number Of Employees | 115 K | |||
| Beta | 0.65 | |||
| Market Capitalization | 167.05 B | |||
| Total Asset | 74.44 B | |||
| Z Score | 6.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.70 % | |||
| Net Asset | 74.44 B | |||
| Last Dividend Paid | 1.92 |
About Abbott Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abbott Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abbott Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abbott Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Abbott Stock
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock. Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Abbott Stock please use our How to Invest in Abbott Laboratories guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.